Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 2Uveal Melanoma 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Cyclophosphamide 5Etoposide 3duvelisib 2Vincristine 2Prednisone 2Melphalan 2Doxorubicin 2Azacitidine 210-propargyl-10-deazaaminopterin 2tazemetostat 1sodium-iodide symporter 1ruxolitinib 1pembrolizumab 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1cemiplimab 1belinostat 1X-Rays 1Whole-Body Irradiation 1Tacrolimus 1Specimen Handling 1Sirolimus 1Prednisolone 1Photons 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Mycophenolic Acid 1Methotrexate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × belinostat × 90 days × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡